The FDA is relaxing some of the requirements of the iPLEDGE program, which is part of the REMS for acne medications containing isotretinoin.[1][7] Patients of reproductive age may, with the consent of a physician, perform mandatory pregnancy tests at home or in other non-medical settings.[1] These changes allow for a more flexible approach to testing instead of a strict medical environment.[1] The iPLEDGE program was originally established in 2005 and approved as REMS in 2010 to minimize the risk of birth defects in fetuses caused by the teratogenicity of isotretinoin.[7] Isotretinoin is used to treat severe nodular acne.[7] The FDA mandates these REMS modifications for the iPLEDGE system.[1]